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Abstract
Objective—To examine differences in psychiatric symptomatology, diagnoses, demographics,
functioning, and psychotropic medication exposure in children with elevated symptoms of mania
(ESM+) compared to youth without ESM (ESM−).
Method—Guardians of consecutively ascertained new outpatients 6 to 12 years of age were
asked to complete the Parent General Behavior Inventory-10 Item Mania Scale (PGBI-10M).
Patients with scores ≥ 12 on the PGBI-10M (ESM+) and a matched sample of screen negatives
(ESM−) were invited to participate.
Results—707 children [621 ESM+, 86 ESM−; mean age 9.4 (2.0) years] were evaluated. The
ESM+ group, compared to the ESM− group, more frequently met DSM-IV criteria for a mood
disorder (p< 0.001), bipolar spectrum disorders (BPSD, p< 0.001), and disruptive behavior
disorders (p<0.01). Furthermore, they showed poorer overall functioning and more severe manic,
depressive, attention deficit/hyperactivity, disruptive behavioral, and anxiety symptoms.
Nevertheless, rates of BPSD were relatively low in the ESM+ group (25%), with almost half of
these BPSD patients (12.1% of ESM+) meeting DSM-IV criteria for bipolar disorder not
otherwise specified (BP-NOS). ESM+ children with BPSD had significantly more: current
prescriptions for antipsychotics, mood stabilizers and anticonvulsants; psychiatric hospitalizations,
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and biological parents with elevated mood; and were lower functioning compared to ESM+
children without BPSD.
Conclusion—Although ESM+ was associated with higher rates of BPSD than ESM−, 75% of
ESM+ children did not meet criteria for BSPD. Results suggest longitudinal assessment is needed
to examine which factors are associated with diagnostic evolution to BPSD in children with ESM
+.
Introduction
Evidence that Elevated Symptoms of Mania (ESM) are present in a substantial number of
children seeking psychiatric care continues to build.1–4 Although a portion of children with
ESM may meet strict DSM-IV criteria for Bipolar Disorder Type 1 or 2 (BP1 or BP2), many
do not. For example, a study of inpatient children found that a relatively high proportion
(62.5%) experienced DSM-III-R symptoms of mania (defined as euphoria and/or irritability
plus three of the remaining five symptoms on the mania symptom subscale from the Child
Symptom Inventory (CAASI-4R)5). However, of those children with manic symptoms, only
a small number met criteria for a bipolar disorder.6
Furthermore, the clinical implications of ESM in children are unclear because the presence
of manic symptoms does not necessarily mean that a bipolar diagnosis is inevitable.3, 7–9 In
one sample of 9- to 13-year-old males meeting DSM-III-R criteria for ADHD and manic
symptoms, no participants met criteria for a bipolar disorder at 6-year follow-up.8 In one of
the few published epidemiological studies, adolescents originally reporting some manic
symptoms (defined as experiencing a distinct period of abnormally and persistently elevated,
expansive, or irritable mood without meeting diagnostic criteria for a bipolar disorder) rarely
developed a bipolar disorder in the 6- to 10-year follow-up period.10
Although relatively little is known about the phenomenology, course of illness, or symptom
evolution of youth who experience ESM but do not meet DSM-IV criteria for a bipolar
diagnosis, it appears that inpatient children with manic symptoms experience marked
psychosocial dysfunction and a high degree of psychopathology regardless of bipolar
diagnostic status.3,6
Though there is currently no clear means of distinguishing which children with ESM will
eventually develop bipolar disorder, determination of a reliable method is a priority due to
the important implications of assigning such a diagnosis to a child. For example, the
diagnosis of bipolar disorder implies a lifelong, heritable condition, with psychological and
social sequelae for both the child and his/her family. Youth who are assigned a bipolar
diagnosis in error may receive inappropriate treatments for years, particularly unnecessary
psychotropic medications that carry with them significant risks. On the other hand, failure to
appropriately assign a BPSD diagnosis may result in a lack of appropriate treatment and
prolonged suffering. Thus, making an accurate diagnosis regarding the presence or absence
of bipolarity in a child manifesting EMS has important clinical implications. However, even
in adults who have putatively more prototypic presentations of bipolar disorder, there are
studies showing that many years typically elapse from the onset of mood symptoms until the
correct BP diagnosis is made.11, 12
Recent data from the National Ambulatory Medical Care Survey (1999–2003) indicated
over 90% of youth who were given a diagnosis of bipolar disorder in office-based clinical
settings received a psychotropic medication for this diagnosis.13 However, data regarding
medication treatment of children with ESM, regardless of diagnosis, are limited. Due to the
presence of symptoms that might be construed as indicative of a bipolar diathesis, it is
possible these children may receive medications indicated for patients with more narrowly
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defined bipolarity. According to treatment recommendations and practice parameters,
children with a bipolar disorder may be prescribed atypical antipsychotics, frequently in
combination with a mood stabilizer.14, 15 Although these agents may be beneficial to some
patients, they also may be associated with substantive risks.
The NIMH-supported Longitudinal Assessment of Manic Symptoms (LAMS) study was
designed to prospectively follow an epidemiologically-ascertained cohort of children with
ESM, as well as a comparison group of outpatient children without elevated manic
symptoms, both to delineate the relationship between manic symptoms and bipolarity and to
carefully define the characteristics of children with ESM. This paper describes the initial
demographic information, diagnostic and symptom prevalence, and medication exposure for
the LAMS cohort that will be followed longitudinally.
Method
Institutional Review Boards at each of the four university-affiliated LAMS sites (Case
Western Reserve University, Cincinnati Children's Medical Center, the Ohio State
University, and the University of Pittsburgh Medical Center/Western Psychiatric Institute
and Clinic) reviewed and approved all procedures in the protocol. Written informed consent
from parents/guardians and assent from participants were obtained before any study-related
procedures were performed. Parents consented to complete the screening procedure
described below; parents consented and children assented to participate in the longitudinal
portion of the study.
Participant Ascertainment
Parents/guardians of all eligible children between the ages of 6 years, 0 months and 12
years, 11 months who were new patients to LAMS outpatient clinics (see inclusion/
exclusion criteria below) were asked to complete the Parent General Behavior Inventory-10
Item Mania Scale (PGBI-10M)16, 17 to screen for ESM. The items that comprise the
PGBI-10M describe hypomanic, manic, and biphasic symptomatology and have been
reported to discriminate bipolar disorder in youth from other diagnoses.17 Each item is
scored from 0 (“never or hardly ever”) to 3 (“very often or almost constantly”); total scores
range from 0 to 30 with higher scores indicative of greater symptomatology. Each patient
whose parent/guardian rated the child at or above a score of 12 (ESM+) on the PGBI-10M
was invited to participate in the longitudinal portion of the LAMS study. In addition, a
smaller comparison group of patients who scored 11 or lower (ESM−) roughly matched in
real time on age, sex, race, ethnicity, and Medicaid status was selected to enroll in the
longitudinal portion of the study. More details concerning subject ascertainment and the
rationale for the cut score of 12 on the PGBI-10M are described in detail in Horwitz et al.4
To be screened for the study, patients must: 1) not have received mental health treatment in
the outpatient clinics where the LAMS study was being conducted within the past 12
months; 2) be between the ages of 6 years, 0 months and 12 years, 11 months; 3) speak
English; 4) have an accompanying parent/guardian who speaks English, and; 5) not have a
sibling or other child living in the same household who had already participated in screening
for possible LAMS participation. See Horwitz et al.4 for a detailed description of these
screening and selection procedures.
Patients rated positively by their parents/guardians for ESM (scoring 12 or higher on the
PGBI-10M; ESM+), and patients not presenting with ESM selected as the comparison group
(ESM−), were invited to participate in the longitudinal portion of the study. Of the 1124
children who screened ESM+, 621 or 55% accepted the invitation. There were no
sociodemographic differences between children/families agreeing to enroll in the
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longitudinal study and those who did not. ESM− children were sampled with replacement
(those who were approached, but refused, were replaced by another demographically
matched youth in the ESM− group) resulting in 86 children without ESM also being
included in the longitudinal cohort4 (see Figure 1).
Longitudinal Assessment and Follow-up
After the children and adolescents were assessed at baseline, participants who continued to
be eligible were seen every six months for up to five years. Each of these study visits lasted
approximately 2–4 hours.
Baseline Assessment
Demographics—Information including age, sex, race, ethnicity, and health insurance
status was obtained from parents/guardians. In addition, a brief medical history was
collected.
Diagnoses—Children and their guardians were administered the Schedule for Affective
Disorders and Schizophrenia for School-Age Children-Present and Lifetime Episode (K-
SADS-PL)18 with additional depression and manic symptom items derived from the
Washington University in St. Louis Kiddie Schedule for Affective Disorders (WASH-U K-
SADS).19, 20 Items to assess nonverbal communication, the child's relationship with others,
shared enjoyment, and social-emotional reciprocity according to DSM-IV criteria were
added to the KSADS-PL to screen for pervasive developmental disorders (PDDs). The
resulting instrument, the K-SADSPL-W, is a semi-structured interview that assesses current
and lifetime psychiatric diagnoses and the time course of each illness.
Unmodified DSM-IV diagnostic criteria were used in the LAMS study. The criteria for BP-
NOS were clarified for the LAMS study to follow the same criteria used in the Course and
Outcome of Bipolar Youth study (COBY).21 BP-NOS was operationalized as follows: (a)
elated mood plus two associated symptoms of mania (e.g., grandiosity, decreased need for
sleep, pressured speech, racing thoughts, increased goal-directed activity, etc.), or irritable
mood plus three associated symptoms of mania; (b) change in the participant's level of
functioning (increase or decrease); (c) symptoms must be present for a total of at least four
hours within a 24-hour period; and (d) the participant must have had at least four episodes of
four hours duration or a total of four days of the above-noted symptom intensity in his/her
lifetime. All diagnoses were reviewed and confirmed by a licensed child psychiatrist or
psychologist. It should be noted that once a child met criteria for a bipolar spectrum disorder
(BPSD) in the LAMS study, that diagnosis was always documented as a current diagnosis
(although it could be listed as “in partial/full remission”).
Medication History—Each child's parent/guardian provided a complete history of the
child's past and currently prescribed psychotropic medications during the interview. For
simplicity, some medications have been grouped according to class (anticonvulsants,
antidepressants, antipsychotics, stimulants, alpha-two agonists, benzodiazepines), whereas
others are reported separately.
Functional Assessment—The Children's Global Assessment Scale (CGAS) was
completed by study interviewers to provide a severity rating of participants' current
impairment22. The CGAS is a clinical rating scale used to document children's overall
functional capacity at home, school, and with peers over the past two weeks. Scores range
from 1 (indicating a severely impaired child) to 100 (indicating a child with superior
functioning).
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Symptomatic Assessment—In addition to administration of the K-SADS-PL-W, which
ascertained presence or absence of manic and depressive symptoms specifically within the
context of a mood episode (i.e., “filtered” ratings), “unfiltered” ratings of apparent mood
symptoms were also assessed via both parental self-report and clinical rating scales. These
unfiltered ratings did not require clinical judgment about the reasons for symptoms to be
manifest. Because a key aspect of the LAMS study is the assessment of symptoms,
regardless of etiology, over time, these unfiltered ratings were obtained to compliment those
assessments of affective illness that were only manifest during the presence of a mood
disorder.
Unfiltered mania ratings were obtained via parental self-report of their child's functioning
over the past six months on the PGBI-10M and via direct interview of parents and children
regarding the past two weeks using the Young Mania Rating Scale (YMRS)23 via interview
with both the child and parent. Total scores on this 11-item scale range from 0 (no manic
symptoms) to 60. The YMRS has demonstrated good reliability24 and good ability to
discriminate bipolar spectrum disorders from attention deficit/hyperactivity disorders
(ADHD).25–27
Unfiltered depression ratings were obtained via direct interview of parents and children
regarding the past two weeks using the Children's Depression Rating Scale-Revised (CDRS-
R).28, 29 The CDRS-R is a 17-item scale administered as an interview with the child and
parent. The instrument has demonstrated good validity and psychometric properties.28, 29
CDRS-R scores range from 17 to 113, with higher scores being indicative of greater
depressive symptomatology.
The Child and Adolescent Symptom Inventory-4R (CAASI-4R)30 contains items reflecting
DSM-IV criteria for emotional and behavioral disorders in children and adolescents. Parent-
reported scores on the attention-deficit/hyperactivity disorder (ADHD), oppositional defiant
disorder (ODD), and conduct disorder (CD) subscales were examined. Frequency of
symptoms and the frequency of symptom-related impairment over the past six months are
scored on a scale of 0 (never) to 3 (very often). The CAASI-4R has demonstrated
satisfactory internal consistency, test-retest reliability, and convergent/discriminant validity
with corresponding scales of the Child Behavior Checklist and the Conners' Parent Rating
Scale.31
The parent-completed Screen for Child Anxiety Related Emotional Disorders (SCARED)32
quantified symptoms of anxiety over the past six months. The SCARED measures five
aspects of anxiety: (1) panic/somatic; (2) generalized anxiety; (3) separation anxiety; (4)
social phobia; and (5) school phobia. The 41 SCARED items are rated from 0 (not true or
hardly ever true) to 2 (very true to often true). The SCARED has shown good internal
consistency (α~0.90)33 and excellent discriminant validity between children with anxiety
disorders and children with non-anxiety psychiatric disorders (all ps < 0.05).33
The Family History Screen (FHS)34 was obtained to collect information on 15 psychiatric
disorders and suicidal behavior in biological parents. As family history will be described in
more detail at a later time, this paper only examines presence or absence of elevated mood
defined as ever have experienced a period of feeling extremely happy or high by the youth's
biological mother or father.
Interviewer Training and Inter-rater Reliability
LAMS interviewers were trained in three parts: during a three-day start-up meeting; by
rating along with taped interviews; and by leading administrations of the assessment
instruments. To prevent rater drift following training, interviewers rated taped
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administrations of the K-SADS-PL-W, CDRS-R, and the YMRS. The kappa for K-SADS-
PL-W psychiatric diagnoses was 0.82. More specifically, the kappa for bipolar diagnoses
was 0.93. In addition, the kappa for the CDRS-R and the YMRS were (k=0.47) and (k=0.41)
respectively, which are within the acceptable levels of item level weighted kappa suggested
in the literature.35
Statistical Analyses
Fisher exact tests were used to test for possible differences in distribution of: sex; race;
ethnicity; Medicaid status; intact families; rates of special education placements, psychiatric
hospitalization, DSM-IV psychiatric diagnoses, family history of elevated mood and current
and past medications in the ESM+ versus ESM− groups and in the ESM+ group with versus
without BPSD. Independent t-tests were used to examine differences in CGAS, YMRS,
PGBI-10M, CDRS-R, CAASI-4R, and SCARED-P scores between ESM+ and ESM−
groups and ESM+ youth with versus without BPSD.
The alpha level for statistical significance was set at p ≤ 0.05. It was not adjusted for
multiple comparisons performed due to the exploratory nature of this work.
Results
Participant Characteristics
Demographics for the 707 participants appear in Table 1. Compared to ESM− participants,
ESM+ participants were significantly less likely to be living in intact families and had
significantly lower CGAS scores, indicative of poorer overall functioning. As ESM+ and
ESM− participants had been matched on demographic variables, these two groups did not
differ significantly in regard to age, sex, race (White versus other races), ethnicity (Hispanic
versus non-Hispanic), or those receiving public insurance (compared to all other insurance
groups). Moreover, the ESM+ and ESM− groups did not differ in the proportion having
received special education or in the number of prior psychiatric hospitalizations (See Table
1).
DSM-IV Psychiatric Disorders
Current diagnoses (as defined by DSM-IV criteria) and symptoms at baseline appear in
Tables 2, 3, and 4. Fourteen participants (9 [1.4%] ESM+ and 5 [5.8%] ESM) did not meet
criteria for a current DSM-IV diagnosis. The average number of current diagnoses at
baseline was 2.5 (standard deviation [SD] = 1.3). Members of the ESM+ group had more
diagnoses (mean=2.6, SD=1.3) than the ESM− comparison group (mean=2.0, SD=1.2;
t=3.95, df=705, p<.001).
Mood Disorders and Mood Symptoms—As shown in Table 2, when compared to
ESM− youth, the ESM+ group more frequently met DSM-IV criteria for a mood disorder
and bipolar spectrum disorders and had significantly higher YMRS scores at baseline. As
expected, the mean PGBI-10M score in the ESM+ group was significantly greater than the
ESM− group. While ESM+ and ESM− groups did not differ significantly in the rate of
depressive disorders, the ESM+ group received significantly higher CDRS-R scores over the
previous two weeks (see Table 2).
ADHD and Disruptive Behavior Disorders—ESM groups did not differ significantly
in rates of current attention-deficit/hyperactivity disorder (ADHD), but the ESM+ group
scored significantly higher on all three CAASI-4R ADHD subscales (see Table 3). In
addition, compared to the ESM− group, the ESM+ group reported more disruptive behavior
Findling et al. Page 6













disorders (53.1% versus 36.0%) and higher oppositional defiant disorder (ODD) and
conduct disorder (CD) subscale scores on the CAASI-4R (see Table 3).
Other Psychiatric Disorders—Table 4 provides comparisons of psychotic, anxiety,
adjustment and pervasive developmental disorders between groups. There was a trend for
the ESM− group to have a greater rate of pervasive developmental disorders (11.6%)
compared to the ESM+ group (5.6%). ESM+ and ESM− groups did not differ significantly
in the occurrence of psychotic disorders, anxiety disorders, or adjustment disorders.
However, SCARED-P total scores were higher in the ESM+ group than in the ESM− group,
indicative of more anxiety symptoms over the previous 6 months. Of note, no participants
met DSM-IV criteria for a substance use disorder.
Psychotropic Medication Exposure
Currently prescribed and past trials of psychotropic medications for participants appear in
Table 5. At baseline, 63% (n=443) of the youth were prescribed at least one psychotropic
medication. Neither current nor past prescription rates differed significantly for ESM+ and
ESM− groups (Current-- ESM+ vs. ESM−: M [SD]=1.1 [1.1] vs. 1.0[1.0]; t=0.38, df=705,
p=0.71; Past-- ESM+ vs. ESM− M[SD]=1.4[2.0] vs. 1.6[2.1]; t=0.62, df=705, p=0.53).
Similarly, prescription rates for specific categories of medication (lithium, anticonvulsants,
antidepressants, antipsychotics, stimulants, or alpha-two agonists) did not differ between
groups (See Table 5).
ESM+ with Bipolar Disorder vs ESM+ without Bipolar Disorder
Table 6 includes the comparisons of demographics, family history, diagnoses, currently
prescribed medication groups, and current mood symptoms for ESM+ participants with and
without BPSD. As shown in Table 6, ESM+ participants with BPSD had more psychiatric
hospitalizations and were older, lower functioning, and more likely to have biological
mothers and fathers with elevated mood (ever experienced a period of feeling extremely
happy or high) than ESM+ participants without BPSD. In addition, ESM+ youth with BPSD
had a higher rate of currently prescribed antipsychotics, mood stabilizers, and
anticonvulsants. Finally, as expected, ESM+ youth with BPSD had higher scores on all
unfiltered mood symptom ratings (PGBI-10M, YMRS, and CDRS-R). However, ESM+
youth without a BPSD had more current disruptive behavior disorders (CD, ODD and/or
disruptive behavior not otherwise specified).
Discussion
These findings underscore several crucial points. ESM appear to be a common concern in
outpatient psychiatric settings, consistent with emerging literature about the relatively high
rate of manic symptoms in other studies. Second, ESM are associated with substantially
increased rates of bipolar disorder, which is why measures assessing ESM may prove useful
as screening aids.17, 36 Third, ESM are associated with other, non-bipolar diagnoses, and/or
may be a marker of severe pathology rather than a specific marker of a bipolar diathesis.
In the 707 children and adolescents of the LAMS cohort, the diagnoses most frequently
assigned at baseline were: ADHD (76.1%), other disruptive behavior disorders (51.1%),
mood disorders (40.5%) and anxiety disorders (31.3%). Further, the entire cohort had high
rates of comorbidity. Of note, the ESM+ group met criteria for more diagnoses and had
poorer overall functioning than the ESM− group. Furthermore, preliminary results indicate
that ESM+ youth with BPSD have lower overall functioning, more psychiatric
hospitalizations, and more parents with elevated mood compared to ESM+ youth without
BPSD.
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Similar to the children described by Carlson & Kelly,6 many youth who were identified as
experiencing ESM did not meet diagnostic criteria for BPSD. Whether or not these children
with ESM will eventually develop a bipolar diagnosis, either confirming or refuting the
findings of Lewinsohn et al.10 and Hazell et al.8 that no or few youth with manic symptoms
will later develop BPSD, will be assessed through longitudinal assessments of this study
cohort. This question is a key specific aim of the LAMS study.
As expected, there were some differences in rates of diagnoses between the ESM groups.
For instance, ESM+ youth were diagnosed with more bipolar spectrum disorders than those
in the ESM− group. However, only one-quarter of youth with ESM actually met diagnostic
criteria for a bipolar spectrum disorder. (Interestingly, most of that quarter of ESM+ children
with BPSD met diagnostic criteria for either BP-NOS (48%) or BP1 (43%), with very few
meeting criteria for BP2 or cyclothymia.) ESM+ youth were, in fact, more likely to have a
disruptive behavior disorder diagnosis than a bipolar diagnosis. More specifically, over half
of the ESM+ group was diagnosed with a disruptive behavior disorder, primarily ODD,
compared to only 36% of the ESM− group.
The ESM+ and ESM− groups did not differ significantly in the number of youth currently
diagnosed with a depressive disorder, ADHD, or anxiety disorder. Despite this lack of
categorical differences between groups, parents of children in the ESM+ group endorsed
significantly greater depressive, ADHD, and anxiety symptoms on the CAASI-4R and
SCARED compared to the ESM− group. This suggests the ESM+ group is more
symptomatic across a variety of domains even if these symptoms do not (yet) translate to
significantly more diagnoses within those domains.
With such diagnostic diversity found in the ESM+ group, it may be argued that the
PGBI-10M cut score was set too low. However, the PGBI-10M cut score of 12 for the ESM
groups was purposely set to keep sensitivity to true bipolar cases high, and also capture a
large number of other cases showing similar symptoms for different diagnostic reasons. The
second, heterogeneous group will be the more interesting one to follow longitudinally.
Not surprisingly, with over three-fourths of LAMS participants meeting diagnostic criteria
for ADHD, stimulants were the most frequently prescribed class of current and past
medication. However, with 76% of the overall sample having an ADHD diagnosis, only
39% of the LAMS cohort was currently prescribed a stimulant. Antipsychotic medications
were prescribed at a relatively high rate, with nearly a quarter (22%) of all 707 LAMS
participants prescribed an antipsychotic at the time of assessment. Although ESM+ and
ESM− groups differed in the rates of bipolar spectrum disorders and disruptive behavior
disorders, neither current nor past exposure to any medication class examined in this study
differed significantly between the groups. However, when examining the ESM+ group,
those children with BPSD were prescribed significantly more antipsychotics (41% vs. 17%),
anticonvulsants, and mood stabilizers compared to ESM+ participants without BPSD.
Finally, although approximately 30% of the participants were diagnosed with an anxiety
disorder and 18% of the youth met criteria for a depressive disorder, rates of current
selective serotonin reuptake inhibitor (SSRI) prescriptions were relatively low (8.9%). This
modest rate may reflect the effect of the Black Box warning for SSRIs.37 A more detailed
examination of community-based prescribing practices is warranted in future examinations
of the LAMS study sample.
When examining the ESM+ group, the fact that the children without a bipolar disorder had a
greater rate of disruptive behavior disorders (DBD) supports the possibility that there are
two main paths that lead to ESM+ : (a) having a bipolar disorder, (b) having DBD and some
mood symptoms without meeting diagnostic symptoms criteria for a bipolar disorder.
Findling et al. Page 8














Limitations of this study include the fact that the sample of children was obtained only from
outpatient mental health centers associated with university partners. Therefore, the sample
does not include children whose parents sought care in other settings or who were currently
hospitalized. The sample was focused in Ohio and Western Pennsylvania and might not
reflect outpatient mental health services utilization patterns in other regions. Further, given
that these were all children and families seeking care, they are not representative of the
general population of children.
Clinical Implications
Although ESM may be commonly found in children and adolescents, this does not
necessarily indicate that BPSD is common in youth. In fact, the children and adolescents in
the ESM+ group were more likely to have an ADHD and/or disruptive behavior disorder
rather than a BPSD. Screening for ESM did increase the base rate of BPSD to a quarter of
the sample, however, higher than would be anticipated in a general outpatient clinic.38
In conclusion, although LAMS participants were selected based on the presence of ESM,
their subsequent structured interviews revealed a diverse range of psychiatric disorders.
Furthermore, while ESM were associated with higher rates of BPSD, most of these youth
did not meet diagnostic criteria for BPSD. Rather, ESM+ youth more commonly had a
disruptive behavior disorder. Perhaps most surprising is the fact that the ESM+ youth did not
differ from ESM− in number of psychotropic medications, a finding that warrants further
investigation. The data will provide the opportunity to examine medication use in youth with
considerable psychiatric morbidity. Results suggest the longitudinal assessment of ESM is
needed to examine which factors are associated with diagnostic evolution to a bipolar
spectrum disorder in patients with ESM+, and whether such evolution even occurs.
Longitudinal data are also needed to identify risk and protective factors associated with
long-term outcomes in this vulnerable population.
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Table 1







86) All Participants (N=707) Statistic, p value
Age, mean (SD) 9.4 (2.0) 9.7 (1.7) 9.4 (1.9) t=1.37, df=705, p=0.17
Male n (%) 413 (66.5) 65 (75.6) 478 (67.6) Fisher's Exact Test p=0.11
White n (%) 395 (63.6) 60 (69.8) 455 (64.4) Fisher's Exact Test p=0.28
Hispanic n (%) 26 (4.2) 5 (5.8) 31 (4.4) Fisher's Exact Test p=0.41
Health Insurance Coverage n (%) Fisher's Exact Test p=0.07
  Medicaid 333 (53.6) 37 (43.0) 370 (52.3)
  Private Insurance 242 (39.0) 41 (47.7) 283 (40.0)
  Private Insurance & Medicaid 39 (6.3) 5 (5.8) 44 (6.2)
  Self Pay 7 (1.1) 3 (3.5) 10 (1.4)
Living with both biological parents
(% yes) 187 (30.1) 36 (41.9) 223 (31.5) Fisher's Exact Test p< 0.05
Ever in special education (% yes) 183 (29.5) 24 (27.9) 207 (29.3) Fisher's Exact Test p=0.80
Psychiatric hospitalizations, mean
(SD) 0.2 (1.3) 0.1 (0.5) 0.2 (1.2) t=0.83, df=705, p=0.41
Overall functioning, CGAS mean
(SD) 54.0 (10.0) 59.0 (11.1) 54.6 (10.3) t=4.29, df=701, p<.001
Family History of Elevated Mood
 Biological Mother n (%) 99 (15.9) 13 (15.1) 112 (15.8) Fisher's Exact Test, p=1.00
 Biological Father n (%) 55 (8.9) 6 (7.0) 61 (8.6) Fisher's Exact Test, p=0.68
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Table 2
Current Mood Diagnoses of Participants with ESM and Comparison Participants
Diagnosis, n (%) ESM+ Participants (n = 621) ESM−Participants (n = 86) Statistic, p value**
Mood Disorders 267 (43.0) 19 (22.1) Fisher's Exact Test p< 0.001
Bipolar Spectrum Disorder 155 (25.0) 7 (8.1) Fisher's Exact Test p<0.001
 BP1 66 (10.6) 5 (5.8)
 BP2 3 (0.5) 0
 Cyclothymia 11 (1.8) 0
 BP NOS 75 (12.1) 2 (2.3)
Manic Symptoms
 PGBI-10M, mean(SD) 13.9 (6.8) 5.3 (5.2) t=11.27, df=690, p <0.001
 YMRS, mean (SD) 17.7 (9.1) 10.4 (7.0) t=7.17, df=705, p<0.001
Depressive Disorder Spectrum * 112 (18.0) 12 (14.0) Fisher's Exact Test p=0.45
 Current MDD 42 (6.8) 7 (8.1)
 Past MDD 13 (2.1) 3 (3.5)
 Current Dysthymia 14 (2.3) 2 (2.3)
 Past Dysthymia 1 (0.2) 0
 Current Depressive Disorder NOS 57 (9.2) 3 (3.5)
 Past Depressive Disorder NOS 6 (1.0) 3 (3.5)
Depressive Symptoms
 CDRS-R, mean (SD) 35.3 (10.7) 30.8 (10.1) t=3.70, df=705, p<0.001
Mood Disorder NOS 11 (1.8) 0
*
One participant met criteria for more than one depressive spectrum disorder diagnosis ESM=elevated symptoms of mania; BP=bipolar disorder;
PGBI-10M=Parent General Behavior Inventory-10 Item Mania Scale; YMRS=Young Mania Rating Scale; MDD = major depressive disorder;
CDRS-R=Children's Depression Rating Scale-Revised.
**
Comparisons between ESM groups were only examined in rates of mood disorders, bipolar spectrum disorders, and depressive disorders
diagnoses as well as mean total PGBI-10M, YMRS and CDRS-R scores.
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Table 3
Current ADHD and DBD Diagnoses of Participants with ESM and Comparison Participants
Diagnosis, n (%)
ESM+ Participants (n =
621)
ESM−Participants (n =
86) Statistic, p value*
Current ADHD Diagnosis 474 (76.3) 64 (74.4) Fisher's Exact Test p=0.69
  Combined Type 278 (44.8) 29 (33.7)
  Inattentive Type 90 (14.5) 18 (20.9)
  Hyperactive/Impulsive Type 45 (7.2) 4 (4.7)
  NOS 61 (9.8) 13 (15.1)
Past ADHD Diagnosis 11 (2.0) 2 (2.4)
ADHD Symptoms, CAASI-4R ADHD Subscales, mean (SD)
 Inattentive 18.2 (6.5) 16.1 (7.3) t=2.81,df=690, p<.01
 Hyperactive-Impulsive 16.7 (6.7) 11.8 (6.9) t=6.24 df=690, p<.001
 Combined 34.9 (11.7) 27.9 (12.8) t=5.11, df=691, p<.001
Disruptive Behavior Disorders 330 (53.1) 31 (36.0) Fisher's Exact Test p<0.01
  ODD 228 (36.7) 18 (20.9)
  Past ODD 12 (1.9) 1 (1.2)
  CD 52 (8.4) 2 (2.3)
  Disruptive Behavior Disorder NOS 50 (8.1) 11 (12.8)
ODD Symptoms, CAASI-4R ODD Subscale, M
(SD) 16.0 (5.8) 11.1 (6.2) t=7.28, df=690, p=<.001
CD Symptoms, CAASI-4R CD Subscale, M (SD) 5.8 (5.2) 2.8 (3.1) t=5.32, df=691, p=<.001
DBD=disruptive behavior disorders; ESM=elevated symptoms of mania; ADHD = attention-deficit/hyperactivity disorder; NOS=not otherwise
specified; ODD = oppositional-defiant disorder; CD = conduct disorder; CAASI-4 = Child & Adolescent Symptom Inventory for DSM-IV.
*
Comparisons between ESM groups were only examined in rates of an ADHD diagnosis, DBD diagnoses, and mean CAASI-4 scores.
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Table 4
Other Most Commonly Found Current Psychiatric Diagnoses of Participants with ESM and Comparison
Participants
Diagnosis, n (%)
ESM+ Participants (n =
621) ESM− Participants (n = 86) Statistic, p value*
Psychotic Disorders 15 (2.4) 1 (1.2) Fisher's Exact Test p=0.071
 Schizophrenia 2 (0.3) 1 (1.2)
 Psychotic Disorder NOS 13 (2.1) 0
Current Anxiety Disorders 198 (31.9) 23 (26.7) Fisher's Exact Test p=0.39
Past Anxiety Disorders 36 (5.8) 9 (10.5) Fisher's Exact Test p=0.10
 Current Post Traumatic Stress Disorder 15 (2.4) 0
 Past Post Traumatic Stress Disorder 9 (1.4) 2 (2.3)
 Acute Stress Disorder 1 (0.2) 0
 Obsessive Compulsive Disorder 11 (1.8) 1 (1.2)
 Current Panic Disorder 6 (1.0) 0
 Past Panic Disorder 3 (0.5) 0
 Current Separation Anxiety Disorder 59 (9.5) 6 (7.0)
 Past Separation Anxiety Disorder 19 (3.1) 4 (4.7)
 Current Specific Phobia 56 (9.0) 10 (11.6)
 Past Specific Phobia 5 (0.8) 4 (4.7)
 Current Social Phobia 15 (2.4) 5 (5.8)
 Past Social Phobia 4 (0.6) 0
 Current Generalized Anxiety Disorder 60 (9.7) 6 (7.0)
 Past Generalized Anxiety Disorder 2 (0.3) 0
 Current Anxiety Disorder NOS 46 (7.4) 1 (1.2)
 Past Anxiety Disorder NOS 10 (1.6) 1 (1.2)
Anxiety Symptoms, SCARED-P, mean (SD) 18.9 (13.7) 12.9 (13.4) t=3.78, df=690, p<.001
Current Adjustment Disorders 11 (1.8) 2 (2.3) Fisher's Exact Test p=0.67
Past Adjustment Disorders 15 (2.4) 1 (1.2)
Pervasive Developmental Disorders 35 (5.6) 10 (11.6) Fisher's Exact Test p=0.05
 Pervasive Developmental Disorder NOS 15 (2.4) 6 (7.0)
 Asperger's Disorder 12 (1.9) 2 (2.3)
 Autistic Disorder 8 (1.3) 2 (2.3)
Elimination Disorders 127 (20.4) 13 (15.2)
 Encopresis 12 (1.9) 1 (1.2)
 Enuresis and Encopresis 11 (1.8) 1 (1.2)
 Past Enuresis 50 (8.1) 8 (9.3)
 Past Encopresis 18 (2.9) 1 (1.2)
Disorders Due to Medical Conditions 6 (1.0) 0
Tourette's Disorder 10 (1.6) 1 (1.2)
Current Chronic Motor or Vocal Tic Disorder 7 (1.1) 0
Past Chronic Motor or Vocal Tic Disorder 2 (0.3) 0
Tic Disorder NOS 3 (0.5) 0
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Diagnosis, n (%)
ESM+ Participants (n =
621) ESM− Participants (n = 86) Statistic, p value*
Transient Tic Disorder 3 (0.5) 0
Past Transient Tic Disorder 11 (1.8) 0
Eating Disorder NOS 3 (0.5) 0
ESM=elevated symptoms of mania; SCARED-P= Screen for Child Anxiety Related Emotional Disorders-Parent.
*
Comparisons between ESM groups were only examined in rates of psychotic disorders, anxiety disorders, adjustment disorders, and
developmental disorders diagnoses and mean SCARED-P total scores.
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Table 6
Demographic and Current Clinical Characteristics of ESM+ Participants with a Current BPSD compared to
ESM+ Participants without BPSD
Characteristics
ESM+ Participants with a
bipolar disorder (n=155)
ESM+ Participants without a
bipolar disorder (n=466) Statistic, p value
Age, mean ± SD 9.7 (2.1) 9.2 (1.9) t=2.70, df=619, p=.007
Male n, (%) 89 (57.4) 324 (69.5) Fisher's Exact Test, p=.008
White n, (%) 110 (71.0) 285 (61.2) Fisher's Exact Test, p=.034
Hispanic n, (%) 5 (3.2) 21 (4.5) Fisher's Exact Test, p=.645
Health Insurance Coverage n (%) Fisher's Exact Test, p=.138
  Medicaid 75 (48.4) 258 (55.4)
  Private Insurance 65 (41.9) 177 (38.0)
  Private Insurance & Medicaid 11 (7.1) 28 (6.0)
  Self Pay 4 (2.6) 3 (0.6)
Living with both biological parents, % yes 53 (34.2) 134 (28.8) Fisher's Exact Test, p=.266
Ever in special education, % yes 53 (34.2) 130 (27.9) Fisher's Exact Test, p=.154
Psychiatric hospitalizations, mean ± SD 0.6 (1.8) 0.1 (1.0) t=3.95, df=619, p<.001
Overall functioning, CGAS mean ± SD 50.8 (9.3) 55.0 (10.1) t=4.48, df=615, p<.001
Family History of Elevated Mood
 Biological Mother n, (%) 39 (25.2) 60 (12.9) Fisher's Exact Test, p=.001
 Biological Father n, (%) 22 (14.2) 33 (7.1) Fisher's Exact Test, p=.013
Diagnoses
Any Attention Deficit Hyperactivity
Disorder 114 (73.5) 360 (77.3) Fisher's Exact Test, p=.383
Any Disruptive Behavior Disorder 68 (43.9) 262 (56.2) Fisher's Exact Test, p=.009
Any Anxiety Disorder 48 (31.0) 150 (32.2) Fisher's Exact Test, p=.842
Any Elimination Disorder 39 (25.2) 88 (18.9) Fisher's Exact Test, p=.107
Any Pervasive Developmental Disorder 5 (3.2) 30 (6.4) Fisher's Exact Test, p=.161
Currently Prescribed Medications
Antipsychotics 64 (41.3) 79 (17.0) Fisher's Exact Test, p<.001
Stimulants 58 (37.4) 179 (38.4) Fisher's Exact Test, p=.849
Mood Stabilizers 26 (16.8) 19 (4.1) Fisher's Exact Test, p<.001
Antidepressants 24 (15.5) 51 (10.9) Fisher's Exact Test, p=.154
Anticonvulsant 21 (13.5) 17 (3.6) Fisher's Exact Test, p<.001
Mood Symptoms
Baseline PGBI-10M total score 17.0 (5.9) 12.9 (6.7) t=6.74, df=606, p<.001
Baseline YMRS total score 26.0 (8.8) 14.9 (7.4) t=15.29, df=619, p<.001
Baseline CDRS-R total score 39.0 (11.1) 34.1 (10.3) t=4.98, df=619, p<.001
ESM=elevated symptoms of mania; BPSD=bipolar spectrum disorders; PGBI-10M=Parent General Behavior Inventory-10 Item Mania Scale;
YMRS=Young Mania Rating Scale; CDRS-R=Children's Depression Rating Scale-Revised
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